Abu Dhabi: Biogenix Labs, a G42 Healthcare company, in collaboration with the Abu Dhabi Quality and Conformity Council (ADQCC), has launched the first Proficiency Testing (PT) program for COVID-19 external testing procedures, reaching out to laboratories across the UAE.

ADQCC was established in 2009 to establish and implement product safety, legal metrology and conformity schemes that inspire consumer confidence. The PT program is aimed at raising the standard of quality assurance for COVID-19 testing in the country, thus guaranteeing the accuracy and efficiency of diagnostic methods.

The PT process involved COVID-19 RT-PCR samples prepared by Biogenix Labs and was sent to over 15 government and private labs across the UAE. The results were then evaluated by ADQCC and sent back to the labs to check their quality standards. The initial survey samples were tested on 5 different platforms, including LamPORE which combines loop-mediated isothermal amplification with nanopore sequencing.

A market leader in the field, Biogenix Labs utilizes many platforms for COVID-19 molecular testing including RT-PCR diagnostic methods, isothermal amplification methods and LamPORE sequencing method. The lab conducts tens of thousands RT-PCR tests per day and has to date processed more than 600,000 samples since commencing services.

Ashish Koshy, CEO of G42 Healthcare, thanked ADQCC for its trust and said, “We are very pleased to collaborate with ADQCC and become the first laboratory in the UAE privileged to provide the COVID-19 PT program. We are ready to step up to the challenge of conducting peer reviews and are honored to set the benchmark in accurate and reliable testing. We will work together with UAE labs to troubleshoot any deficiencies discovered and raise testing standards to ensure that a high degree of safety, accuracy and efficiency is adopted for population-scale detection and diagnosis across the UAE.”

Biogenix Labs, part of G42 Healthcare, upholds the health of the community by maintaining the highest standards of quality and efficiency. It was also the first lab to achieve ISO15189 accreditation for COVID RT PCR and COVID antibodies (IgG & IgM) from the Emirates National Accreditation System (ENAS), the federal accreditation body of the UAE, and is compliant with Department of Health – Abu Dhabi (DOH) protocols and the international standards. This assures a high degree of confidence and reliability in the test results, a critical element in fighting the COVID-19 pandemic.

Located in the sustainable city of Masdar, Biogenix Labs operates to Biosafety Level 3 standards and is changing the landscape and meaning of reference laboratories with the fastest turnaround time, quality testing procedures and efficient processes. Its’ state-of-the-art equipment and processes include fully automated extractors, real-time PCR, liquid handlers, immunoassay, chemistry and hematology analyzers.

G42 Healthcare  

G42 Healthcare, a subsidiary of Abu Dhabi-based Group 42, a leading technology company, is committed to developing a world-class, sustainable healthcare sector in the UAE and abroad. At the forefront of the battle against COVID-19, G42 Healthcare partnered with health authorities and specialized medical facilities in Abu Dhabi to establish a massive throughput testing laboratory in just 14 days and contribute to the 4Humanity trial effort of the UAE.

G42 Healthcare uses its advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conduct research into new vaccines and drug therapies, and map trends in the outbreak, including virus mutations. The company has also developed its own PPE manufacturing capacity.

Beyond COVID-19, G42 Healthcare has developed a program of activities to support the health of future generations – ranging from genomics, imaging and diagnostics to digitization programs, manufacturing and cutting-edge research.

For further information on G42, visit www.g42.ai 

For further details, please contact:
Mona Mashhoor
Email: mona.mashhoor@viola.ae 

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.